FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2–Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study GroupRalf‐Dieter Hofheinz, Salah‐Eddin Al‐Batran, Gabriele Margareta Siegler et al.|Journal of Clinical Oncology|2022Cited by 97
Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: Final results of the PETRARCA multicenter randomized phase II trial of the AIO.Ralf‐Dieter Hofheinz, Salah‐Eddin Al‐Batran, Georg Martin Haag et al.|Journal of Clinical Oncology|2020Cited by 91
Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma: Petrarca—A phase II trial of the German AIO.Ralf‐Dieter Hofheinz, Salah‐Eddin Al‐Batran, Gerrit zur Hausen et al.|Journal of Clinical Oncology|2017Cited by 12
Efficacy and quality of life for FOLFOX/bevacizumab +/− irinotecan in first-line metastatic colorectal cancer—final results of the AIO CHARTA trialHans‐Joachim Schmoll, Joseph Tintelnot, Julia Mann et al.|British Journal of Cancer|2023Cited by 11